Literature DB >> 15460318

Characterization of a wild-type strain of Francisella tularensis isolated from a cat.

Thomas J Inzana1, Gretchen E Glindemann, Gerald Snider, Susan Gardner, Lisa Crofton, Barbara Byrne, Joseph Harper.   

Abstract

Francisella tularensis type A is the primary cause of tularemia in animals and humans in North America. The majority of research on F. tularensis has been done with the attenuated live vaccine strain (LVS), which is a type B, but very few wild-type F. tularensis strains have been characterized. A gram-negative coccobacillus that was isolated in pure culture from the lungs of a cat that died after being lost for 5 days was received for identification at the Virginia-Maryland Regional College of Veterinary Medicine Teaching hospital. The isolate (strain TI0902) was not identified (or was misidentified) by commercial identification systems; however, it was identified as F. tularensis subspecies tularensis (type A) by sequencing a portion of the 16S ribosomal RNA gene. Furthermore, repetitive extragenic palindromic sequences-polymerase chain reaction amplified a 4-kb DNA fragment from TI0902 that was characteristic of F. tularensis type A but not type B. The electrophoretic profile of the lipopolysaccharide of strain TI0902 was identical to that of the LVS by Western blotting with antiserum to LVS. The protein-enriched outer membrane of strain TI0902 contained 6-8 proteins, which were similar in molecular size to those from the LVS. Electron microscopy of negatively stained and alcian blue-stained LVS and TI0902 cells showed that both strains were coccobacillary in shape and may be encapsulated. However, after mouse challenge, the TI0902 strain was clearly more virulent than the LVS strain. Results of this study indicate that the genotype and phenotype of wild-type F. tularensis type A strain TI0902 is similar, but not identical, to that of the LVS strain. Further studies will help determine whether pathogenesis and host-pathogen interactions are also similar between the 2 strains.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15460318     DOI: 10.1177/104063870401600502

Source DB:  PubMed          Journal:  J Vet Diagn Invest        ISSN: 1040-6387            Impact factor:   1.279


  6 in total

1.  Multiple mechanisms of NADPH oxidase inhibition by type A and type B Francisella tularensis.

Authors:  Ramona L McCaffrey; Justin T Schwartz; Stephen R Lindemann; Jessica G Moreland; Blake W Buchan; Bradley D Jones; Lee-Ann H Allen
Journal:  J Leukoc Biol       Date:  2010-07-07       Impact factor: 4.962

2.  Genomic comparison between a virulent type A1 strain of Francisella tularensis and its attenuated O-antigen mutant.

Authors:  Thero Modise; Cheryl Ryder; Shrinivasrao P Mane; Aloka B Bandara; Roderick V Jensen; Thomas J Inzana
Journal:  J Bacteriol       Date:  2012-05       Impact factor: 3.490

3.  Isolation and mutagenesis of a capsule-like complex (CLC) from Francisella tularensis, and contribution of the CLC to F. tularensis virulence in mice.

Authors:  Aloka B Bandara; Anna E Champion; Xiaoshan Wang; Gretchen Berg; Michael A Apicella; Molly McLendon; Parastoo Azadi; D Scott Snyder; Thomas J Inzana
Journal:  PLoS One       Date:  2011-04-22       Impact factor: 3.240

4.  Tularemia among free-ranging mice without infection of exposed humans, Switzerland, 2012.

Authors:  Francesco C Origgi; Barbara König; Anna K Lindholm; Désirée Mayor; Paola Pilo
Journal:  Emerg Infect Dis       Date:  2015-01       Impact factor: 6.883

5.  Glycosylation of a Capsule-Like Complex (CLC) by Francisella novicida Is Required for Virulence and Partial Protective Immunity in Mice.

Authors:  Kelly C Freudenberger Catanzaro; Anna E Champion; Nrusingh Mohapatra; Thomas Cecere; Thomas J Inzana
Journal:  Front Microbiol       Date:  2017-05-30       Impact factor: 5.640

6.  Further Characterization of the Capsule-Like Complex (CLC) Produced by Francisella tularensis Subspecies tularensis: Protective Efficacy and Similarity to Outer Membrane Vesicles.

Authors:  Anna E Champion; Aloka B Bandara; Nrusingh Mohapatra; Kelly M Fulton; Susan M Twine; Thomas J Inzana
Journal:  Front Cell Infect Microbiol       Date:  2018-06-15       Impact factor: 5.293

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.